Vertex announces positive results from viral kinetic study of the nucleotide analogue als-2200 in people with hepatitis c

Cambridge, mass.--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and its collaborator alios biopharma, inc. today announced positive results from a viral kinetic study of the nucleotide analogue als-2200 for the treatment of hepatitis c. there was a median 4.54 log10 reduction in hepatitis c virus (hcv) rna in people with genotype 1 chronic hepatitis c who were new to treatment (n=8) after seven days of dosing with 200 mg of als-2200 once daily. als-2200 was well-tolerated in this study, and no patients discontinued due to adverse events. based on these data, vertex plans to begin phase 2 studies this year of 12-week all-oral regimens including als-2200 in people with genotype 1 hepatitis c, pending discussions with regulatory agencies. patients with hepatitis c dosed with als-2200 in this study had a dose-dependent, consistent and rapid decline in hcv rna. after three days of dosing, a median 3.85 log10 decline was observed among patients in the 200 mg dose group. in this dose group, a median 4.54 log10 decline was observed after seven days of dosing, which was maintained for up to two days after the completion of dosing. four of eight patients in this dose group achieved hcv rna levels below the limit of quantification (
VRTX Ratings Summary
VRTX Quant Ranking